Cryosite Limited (CRYOSITE FPO [CTE]) Aktie

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.